Malignant neoplasms arising in a cohort under investigation in England may be ascertained through contact with members of the cohort, with the employer or organization from which the cohort is derived, with one or more of the 11 regional cancer registries covering the population, or by using a combination of these methods. However, the National Health Service Central Register (NHSCR) for England and Wales, based at Southport, can also notify bona fide investigators of cancer registrations and deaths among members of a defined cohort. After approval of the study protocol by the British Medical Association's Ethical Committee and by the Office of Population Censuses and Surveys (OPCS), the NHSCR record of each individual in the cohort can be marked with a code indicating membership of the study cohort, ('flagged'). In theory, the NHSCR receives copies of all death certificates and, since 1971, all cancer registrations, to enable cancer survival statistics to be generated (Balarajan & Scott, 1983) ; when a death certificate or a cancer registration relates to a flagged individual, the investigator is notified (notifications are made at quarterly intervals). About 96% of the 200,000 cancer registrations in England and Wales each year are successfully traced to an individual's record at NHSCR (Swerdlow, 1986) , and provided all the members of a cohort can be similarly traced for flagging of their records, virtually complete ascertainment of cancer registrations and deaths in the cohort should be assured.
About 200 studies have used this system since 1971. There has recently been some interest in assessing its efficiency in practice, since the accuracy of investigations which depend solely on the NHSCR for information on cancer incidence and death may be seriously affected by incompleteness of regional cancer registration, and by delays or errors in the various stages between registration and notification. A recent study of 50 confirmed breast cancers in a flagged cohort of some 4,500 women followed up for an average of 5.9 years showed that more than half the cancers had not been notified within two and a half years of diagnosis, and that 14 had not been registered at all (Hunt & Coleman, 1987) ; this study was restricted to breast cancer, however, and involved a relatively small number of elderly women with an unrepresentative geographic distribution. In this report, we provide an assessment of the cancer notification system using data from the Oxford-Family Planning Association (Oxford-FPA) study of contraception, in which 17,000 married women aged 25-39 years were recruited at 17 family planning clinics from 1968 to 1974, and flagged at the NHSCR in Southport. The women in the study have been followed up annually at the clinics, or by post, telephone or home visits, to collect data on the reasons for all hospital visits (inpatient or outpatient), on contraceptive practices and on several other related matters. Information has been provided voluntarily by each subject with a high standard of completeness and accuracy (Vessey et al., 1974) . Less than 10% of the women have been lost to follow up (including those who have emigrated) in the past 20 years. All self-reported cancer diagnoses have been confirmed by histology, and all diseases and deaths have been coded by one investigator (MV). The methods used in the Oxford-FPA study have been described in detail elsewhere (Vessey et al., 1976) . Direct ascertainment of malignant neoplasms in this large population, which had been flagged at the NHSCR since the inception of the current scheme in 1971, offered a unique opportunity to examine the completeness and timeliness of both cancer registration and notification.
Population and methods
When the cohort was originally flagged at the NHSCR, 199 (1.2%) of 17,032 women were not traced. After provision of additional details in 1986, the entire cohort is now flagged.
A The proportion of neoplasms not registered is shown for each registry in Table IV . Neoplasms ascertained directly were assigned to the registry in the territory of which the woman was living at the time of diagnosis. Overall, 13.5% of the 325 tumours were not registered. Excluding the (B) and (I) registries, in which less than 10 tumours were eligible for registration, under-registration ranged from 2% (D) to 42% (K). The women in the Oxford-FPA study are not a random sample of the female population of childbearing age, and more participating clinics drew their clientele from the (C) region than any other. The sample of tumours is thus small for most individual registries, and three of the four registries at which 30 or more tumours were eligible for registration (C, D, J) had registered 90% or more of those tumours. However, under-registration was 42% (10/24) at (K) and 23% (10/43) at (H). Only three (7%) of the 44 unregistered 1968-9 1970-4 1975-9 1980 1981 1982 1983 1984 1985 Total However, since the study population consisted only of married women of childbearing age, and was not evenly distributed among cancer registry territories, the figure of 86.5% is not a simple estimate of the completeness of female cancer registration in England. For example, only 11 (3%) of 325 cancers were diagnosed in the area covered by one of the larger registries, (E), which covers about 30% of the female population. Completeness of cancer registration and the size of population covered both vary considerably between the regional registries (OPCS, 1981) . Several adjusted estimates were calculated to take account of the female population distribution between registries; these estimates differed by only 5% or so from the crude estimate, but they were sensitive to small changes in the criteria for inclusion of registries in the estimate (more than 10, 20 etc. tumours eligible for registration), and are not reported in detail.
The site distribution of tumours in this population is also somewhat atypical, with melanoma and breast cancer more common, and cancer of the cervix, uterus and bowel less common than in the general population, and since completeness of registration varies by site, this might also affect the estimate of completeness. However, with the proviso that the study population is not fully representative of all women in England by age, marital status, cancer risk or geographic distribution, the overall estimate of 86.5% for the completeness of female cancer registration in England seems reasonable. Cancers in this study population might be more readily diagnosed simply because the women were regularly attending family planning clinics, but these clinics do not provide information to cancer registries, and there is therefore no reason to suppose that cancers diagnosed in this population are more or less likely to be registered as a result of the woman being in the study than cancers in other women. It should be noted that the cancers recorded in this study were diagnosed over a 19-year period, but the estimate of completeness is heavily weighted by the period 1980-84, during which almost half the tumours were diagnosed (Table II) .
We are not aware of any recent attempt at direct assessment of the completeness of cancer registration for England. Estimates for individual registries have been made: the most detailed of these suggest a level of ascertainment of about 94% for the N. Western registry (Nwene & Smith, 1982; Benn et al., 1982) . Other values have been given for Trent (close to 100%; Trout, 1982) and W. Midlands (98%; Waterhouse, 1982) , but although levels of reporting in these registries are probably high, details of how these estimates were obtained are not given. On the basis of such estimates and the regional variation in the ratio of cancer deaths to cancer registrations, it has been suggested that in some regions completeness of ascertainment might be as low as 60-70 per cent (OPCS, 1981) , although two registries acknowledged as defective in the past have since been reorganized and merged with the Thames registry. Donnan (1982) showed that at least part of the regional variation in cancer rates was likely to be due to deficient registration, but concluded that completeness of national ascertainment had increased between 1968 and 1976.
In Stockholm County, Sweden, completeness of registration in 1978 was estimated at 96% or more (Mattsson et al., 1985) after direct examination of hospital record systems for over 6,000 cases first treated in 1978 and followed up for five years. This precise estimate refers to a single year for the main population centre (1.5 million) in a small country with highly developed health and registration systems. The estimate of completeness of registration provided here for England is based on a much smaller sample of cases, diagnosed over a long period of time, with an unrepresentative distribution by region, tumour site and age, and limited to females, but it is derived from direct ascertainment of malignant neoplasms from the subjects themselves, with histological confirmation.
Under-registration varied considerably by tumour site. Non-melanoma skin cancers are known to be underregistered, and nine (36%) of 25 were not registered in this population, but eight (40%) of 20 melanomas were not registered either, and this is surprising. The high proportions of unregistered tumours of lung (50%) and non-Hodgkin's lymphoma (38%) are based on only six and eight cases respectively. Only 12 (8%) of 150 breast cancers were not registered, compared with 14 (28%) of 50 breast cancers reported by Hunt & Coleman (1987) . Cancer ascertainment in the larger study reported here is likely to have been more complete, however, and the figure of 8% for breast cancer is considered more reliable.
The only other distinguishing feature of the unregistered tumours was that eight (18%) were treated in private hospitals. There is already some concern that cancers in patients treated privately are not being registered (Balarajan & Scott, 1983 ) and a similar proportion (21%) of privately treated patients was observed among unregistered breast cancers reported by Hunt & Coleman (1987) , although this was based on small numbers.
The accuracy of cancer registration would appear high. Only two site-codes assigned to tumours within this study and at cancer registration differed at the third digit of ICD-8, and there was one major error in date of diagnosis; minor differences in dates of birth or of diagnosis were common, however. Some cancers were notified twice, although the later notification was clearly for a recurrence of the original tumour; only 11 true second primary neoplasms were recorded.
Before an investigator can learn of a cancer from the national registration scheme, it must be diagnosed, recorded in the regional cancer registry, forwarded to the OPCS national registry, passed to the NHSCR, flagged there and finally notified to the investigator. There is clearly potential for error and delay in this system, and it is worth considering the fate of the 281 cancer registrations detected during this exercise. There was a marked decline in the proportion of registrations notified to us over a 15-year period, from 98% in 1970-74 to 68% in 1980-84, though only about 50% of notifications arrived within 2.5 years of diagnosis (Table  III) , and the final proportion for 1980-84 may eventually be higher than 68%. Overall, 219 (78%) of cancer registrations were notified to us, whereas over 98% of all cancer registrations sent to NHSCR were apparently flagged for the period 1971-78, with very little variation between consecutive years or between different registries (OPCS, unpublished. tables). These observations are difficult to reconcile, unless either (a) a proportion of tumour registrations received by OPCS from the regional registries is not forwarded to the NHSCR, or (b) the final step of notifying the investigator is omitted in a proportion of cases. The timeliness of notification has improved since the system of flagging began in 1971. Many tumours diagnosed in the early 1970s were only notified four years later, and the range of delays was wide (4-87 months). More recently, mean lag-times have been shorter (1.5 years in 1975-79 and 2.5 years in 1980-85) and the range narrower (12-52 months). It should be noted that a large number of cohorts is currently flagged at the NHSCR, involving many thousands of subjects (see OPCS, 1981) . As Donnan (1982) has pointed out, the staff engaged in tracing cancers in flagged cohorts and notifying them to the investigators are also employed for updating the National Cancer Register, and the combined workload is considerable.
It is perhaps worth emphasizing our opinion that the notification service for deaths and cancer registrations provided since 1971 by the National Health Service Central Register has been and remains of immense value in many epidemiological studies involving long-term follow-up of large numbers of persons, providing for most of them crucial information which could often not have been obtained, as was possible in this study, in any other way. The particular design adopted for this study made it possible for the efficiency of the notification scheme to be assessed, and the twin purpose in presenting these results is first, to provide other investigators who use the scheme with information about it which is not usually available, and second, to assist the Office of Population Censuses and Surveys, which operates the scheme, to identify and correct its weaknesses.
Since investigators can only be notified of a cancer by the NHSCR if it has first been registered, the variable degree of completeness of cancer registration between the different regional registries should also be considered in the interpretation of studies using the NHSCR for ascertainment of cancers. Our estimate of 86.5% for the completeness of cancer registration in England strictly applies only to women of childbearing age; it should be interpreted in the light of unrepresentative geographic distribution of subjects and the long time period covered, although most of the cancers involved were diagnosed since 1980. It might be valuable if direct assessment of the completeness of cancer registration could also be derived from other large cohort studies in which cancers have been ascertained independently of the cancer registration scheme.
